CombinatoRx To Present Data For Oncology Programs At American Association For Cancer Research Meeting

CombinatoRx, Incorporated (NASDAQ: CRXX) today announced that preclinical data on its discovery of novel synergistic drug combinations for the treatment of cancer will be highlighted at the 101 ^st Annual meeting of the American Association for Cancer Research 2010, April 17-21, in Washington, DC. These preclinical studies reinforce the rationale for investigation of A2A and β2AR agonists in the treatment of multiple myeloma and other B-cell malignancies and highlight the power of the CombinatoRx combination high throughput screening (cHTS™) technology to interrogate combination activity across large panels of cancer cells to identify novel mechanisms for therapeutic application.

Poster Presentation:

• Abstract #5509: Wednesday, April 21, 2010, 8:00 AM - 11:00 AM, “Identification of synergistic drugs using combination high-throughput screening,” Rickles, et.al., Exhibit Hall A-C, Poster Section 25, , Poster Board 29.

About CombinatoRx

CombinatoRx, Incorporated (CRXX) develops novel drug candidates with a focus on the treatment of pain and inflammation. The company applies its combination drug discovery capabilities and its selective ion-channel modulation platform to generate innovative therapeutics. To learn more about CombinatoRx, please visit www.combinatorx.com.

Forward-Looking Statement:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 concerning CombinatoRx, the CombinatoRx cHTS drug discovery technology, and the business plans of CombinatoRx. These forward-looking statements about future expectations, plans, objectives and prospects of CombinatoRx may be identified by words like "believe," "expect," "may," "will," "should," "seek," or “could” and similar expressions and involve significant risks, uncertainties and assumptions, including risks related to the unproven nature of the CombinatoRx cHTS drug discovery technology, the Company's ability to obtain additional financing or funding for its research and development and those other risks that can be found in the "Risk Factors" section of the Company’s annual report on Form 10-K on file with the Securities and Exchange Commission and the other reports that CombinatoRx periodically files with the Securities and Exchange Commission. Actual results may differ materially from those CombinatoRx contemplated by these forward-looking statements. These forward looking statements reflect management’s current views and CombinatoRx does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release except as required by law.